Evidence map›Paper›PMID 30170549›Full record

ArticleBMC infectious diseases2018

Treatment outcome of multidrug-resistant tuberculosis in Japan - the first cross-sectional study of Japan tuberculosis surveillance data.

Lisa Kawatsu, Kazuhiro Uchimura, Kiyohiko Izumi, Akihiro Ohkado, Takashi Yoshiyama

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Lisa KawatsuDepartment of Epidemiology and Clinical Research, the Research Institute of Tuberculosis, 3-1-24, Matsuyama Kiyose, Tokyo, Japan. kawatsu@jata.or.jp.ORCID http://orcid.org/0000-0003-2666-844X
Kazuhiro UchimuraDepartment of Epidemiology and Clinical Research, the Research Institute of Tuberculosis, 3-1-24, Matsuyama Kiyose, Tokyo, Japan.
Kiyohiko IzumiDepartment of Epidemiology and Clinical Research, the Research Institute of Tuberculosis, 3-1-24, Matsuyama Kiyose, Tokyo, Japan.
Akihiro OhkadoDepartment of Epidemiology and Clinical Research, the Research Institute of Tuberculosis, 3-1-24, Matsuyama Kiyose, Tokyo, Japan.
Takashi YoshiyamaDepartment of Epidemiology and Clinical Research, the Research Institute of Tuberculosis, 3-1-24, Matsuyama Kiyose, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMultidrug resistant-tuberculosis (MDR-TB) is a major global health concern. Its treatment requires toxic medications, is longer and costlier than drug-susceptible TB, and often results in productivity losses and poor outcomes. In Japan, a TB middle-burden country, reports on treatment outcome of MDR-TB patients have only been institution-based. We thus sought to shed some light on the nationwide treatment status and outcome of MDR-TB patients in Japan.

methodsCharacteristics and treatment status and outcome of MDR-TB patients notified between 2011 and 2013 were evaluated using the data from the Japan TB Surveillance (JTBS) system. Since the treatment outcome from the surveillance data was not directly linked to any clinical records or drug susceptible test results, we also analyzed the treatment duration of MDR-TB cases in an attempt to validate our results.

resultsBetween 2011 and 2013, a total of 172 MDR-TB patients had been notified to the JTBS as MDR-TB. 68.6% (118/172) were males and 70.9% (122/172) were Japan-born - however, over the study period, the proportions of foreign-born, of those in the age group 15-64 years old and of new cases have increased. The overall treatment completion rate was 57.0%, however, when restricted to patients aged 64 years old and below, the rate improved to 71.6%. Treatment duration of 29.2% of those patients who had been recorded as "treatment completed" in fact fell short of the 540 days, the minimum duration as recommended by the Japanese guideline.

conclusionsIncreasing proportion of new cases, and of younger age groups among the MDR-TB patients indicate new transmissions. Better strategies for early detection and containment of MDR-TB are urgently needed. The overall treatment completion rate was 57.0% over the three-year study period. However, when restricting the result to those aged 64 years old and below, the rate improved to 71.6%, which was comparable to similarly industrialized countries. Due to the limitations of the JTBS data, a comprehensive survey of all MDR-TB patients may be necessary to provide more concrete evidence for decision-making.

Indexed as

AdolescentAdultAgedAged, 80 and overAntitubercular AgentsCross-Sectional StudiesDatabases, FactualFemaleHumansJapanMaleMiddle AgedPopulation SurveillanceTreatment OutcomeTuberculosisTuberculosis, Multidrug-ResistantAntitubercular AgentsEpidemiologyMultidrug-resistanceSurveillanceTreatment outcomeTuberculosis

Identifiers

PMID30170549
PMCPMC6119256

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.